137 related articles for article (PubMed ID: 36422297)
1. Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis.
Wang F; Zhang H; He B; Liu Z; Wu X; Liu Y; Xu X; Gou X; Wang H; Yang Q
Hematol Oncol; 2023 Aug; 41(3):474-486. PubMed ID: 36422297
[TBL] [Abstract][Full Text] [Related]
2. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
Wen QJ; Yang Q; Goldenson B; Malinge S; Lasho T; Schneider RK; Breyfogle LJ; Schultz R; Gilles L; Koppikar P; Abdel-Wahab O; Pardanani A; Stein B; Gurbuxani S; Mullally A; Levine RL; Tefferi A; Crispino JD
Nat Med; 2015 Dec; 21(12):1473-80. PubMed ID: 26569382
[TBL] [Abstract][Full Text] [Related]
3. Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins.
He B; Wang C; Wang F; Tian L; Wang H; Fu C; Liu J; Xi C; Zhu C; Yang Q
J Control Release; 2023 Apr; 356():554-566. PubMed ID: 36924895
[TBL] [Abstract][Full Text] [Related]
4. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.
Gangat N; Marinaccio C; Swords R; Watts JM; Gurbuxani S; Rademaker A; Fought AJ; Frankfurt O; Altman JK; Wen QJ; Farnoud N; Famulare CA; Patel A; Tapia R; Vallapureddy RR; Barath S; Graf A; Handlogten A; Zblewski D; Patnaik MM; Al-Kali A; Dinh YT; Englund Prahl K; Patel S; Nobrega JC; Tejera D; Thomassen A; Gao J; Ji P; Rampal RK; Giles FJ; Tefferi A; Stein B; Crispino JD
Clin Cancer Res; 2019 Aug; 25(16):4898-4906. PubMed ID: 31061068
[TBL] [Abstract][Full Text] [Related]
5. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
6. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
[TBL] [Abstract][Full Text] [Related]
7. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
[TBL] [Abstract][Full Text] [Related]
9. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.
Krause DS; Crispino JD
Clin Cancer Res; 2013 Nov; 19(22):6084-8. PubMed ID: 23963861
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation.
Goldenson B; Kirsammer G; Stankiewicz MJ; Wen QJ; Crispino JD
Blood; 2015 Mar; 125(13):2141-50. PubMed ID: 25670627
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.
Masselli E; Carubbi C; Gobbi G; Mirandola P; Galli D; Martini S; Bonomini S; Crugnola M; Craviotto L; Aversa F; Vitale M
Leukemia; 2015 Nov; 29(11):2192-201. PubMed ID: 26183534
[TBL] [Abstract][Full Text] [Related]
13. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.
Bae E; Park CJ; Cho YU; Seo EJ; Chi HS; Jang S; Lee KH; Lee JH; Lee JH; Suh JJ; Im HJ
Int J Lab Hematol; 2013 Dec; 35(6):629-36. PubMed ID: 23693053
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
16. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.
Wernig G; Kharas MG; Mullally A; Leeman DS; Okabe R; George T; Clary DO; Gilliland DG
Leukemia; 2012 Apr; 26(4):720-7. PubMed ID: 22005786
[TBL] [Abstract][Full Text] [Related]
17. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner.
Chai RC; Kouspou MM; Lang BJ; Nguyen CH; van der Kraan AG; Vieusseux JL; Lim RC; Gillespie MT; Benjamin IJ; Quinn JM; Price JT
J Biol Chem; 2014 May; 289(19):13602-14. PubMed ID: 24692538
[TBL] [Abstract][Full Text] [Related]
18. CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.
Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR
J Cell Physiol; 2010 Nov; 225(2):490-9. PubMed ID: 20458749
[TBL] [Abstract][Full Text] [Related]
19. Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.
Ciaffoni F; Cassella E; Varricchio L; Massa M; Barosi G; Migliaccio AR
Blood Cells Mol Dis; 2015 Mar; 54(3):234-41. PubMed ID: 25703685
[TBL] [Abstract][Full Text] [Related]
20. Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly.
Kawano N; Saito N; Yoshida S; Kitanaka A; Shide K; Marutsuka K; Ohshima K; Shimoda K
Tohoku J Exp Med; 2022 Feb; 256(2):119-125. PubMed ID: 35173090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
